Lotus Pharmaceutical Co Ltd (1795.TW) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · Taiwan · ISIN TW0001795003

Price
168.50 TWD
Market cap
44.09 bn TWD
P/E (2025)
9.34
P/S (2025)
2.15
Dividend yield
1.52 %
Net margin
23.01 %
Return on equity (ROE)
19.85 %
Return on assets (ROA)
4.45 %

Lotus Pharmaceutical Co Ltd financials

Fiscal year20242025
Revenue18.58 bn TWD20.51 bn TWD
Gross profit10.92 bn TWD10.64 bn TWD
Operating income6.02 bn TWD5.90 bn TWD
EBIT6.93 bn TWD5.90 bn TWD
Net income5.07 bn TWD4.72 bn TWD
Diluted EPS – continuing operations19.23 TWD18.04 TWD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Lotus Pharmaceutical Co Ltd

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. In addition, it offers management consultancy services; pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.